Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Sanofi SA (SNY) vs Vanguard Total World Stock Index Fund ETF (VT) Price & Performance

Vanguard Total World Stock Index Fund ETFTrade

Price performance (Past 24H)

Key statistics

Sanofi SA vs Vanguard Total World Stock Index Fund ETF — how do they compare? Sanofi SA trades at $43.49 (market cap $104.30B), while Vanguard Total World Stock Index Fund ETF trades at $161.45. The key difference: Sanofi SA pays a 5.55% dividend while Vanguard Total World Stock Index Fund ETF pays none, and Vanguard Total World Stock Index Fund ETF is trading nearer its 52-week high, Sanofi SA nearer its low. Which is the better fit depends on your goals.

SNYVT
Market Cap
$104.30B
Sector
HealthBroad Market / Factor
52-Week High
$52.34$161.30
52-Week Low
$41.33$132.19
Enterprise Value
$124.19B
Dividend Yield
5.55%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Sanofi SA

SNY trades at $43.48, showing minimal daily change. The technical outlook is neutral with mixed signals, while the stock hovers near its pivot point of $44. Fundamentally, the company reported strong Q2 2026 earnings, beating estimates with EPS of $1.21 versus $1.10 expected, and raised its 2026 sales guidance. Revenue for 2025 was $46.72B with a net income margin of 16.72%, though a decline is projected for 2026. Recent news highlights regulatory approvals for new drugs and strategic shifts under a new CEO.

The investment outlook is cautiously optimistic, supported by earnings beats and positive guidance, but tempered by a projected profit margin contraction in 2026 and a neutral analyst consensus. Key opportunities include growth from Dupixent and new drug approvals, while risks involve pipeline setbacks, competitive pressures, and potential legal challenges. The stock presents a value case with a reasonable P/E of 23.27, but requires monitoring of execution under new leadership.

Vanguard Total World Stock Index Fund ETF

VT trades at $161.59, up 0.39% on the day, with a bullish technical signal driven by moving averages. The ETF's broad diversification across over 10,000 global stocks provides stability, though RSI levels indicate potential overbought conditions. Recent news highlights institutional activity, including Barry Investment Advisors reducing its stake by 18.7% in Q2 2026 (SEC filing, August 10, 2026).

Outlook remains positive due to global exposure and low expense ratio, but risks include trade war uncertainties and seasonal volatility. Analysts note fair valuation with a mid-to-high teens P/E and 11.4% long-term EPS growth (Seeking Alpha, July 25, 2026).

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Sanofi SA

Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.

Read more on SNY

About Vanguard Total World Stock Index Fund ETF

VT is a foundational, low-cost ETF that seeks to track the FTSE Global All Cap Index, providing exposure to nearly 10,000 stocks across developed and emerging markets worldwide, including the United States. It serves as a single-ticker solution for total global equity diversification, capturing approximately 98% of the world's investable market capitalization.

Read more on VT